Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

Overview of attention for article published in Annals of Surgical Oncology, June 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 24 X users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 26 X posts from 24 X users, with an upper bound of 289,787 followers.

RT @SyedAAhmad5: Immunotherapy for HCC. The future is now. ⁦@AnnSurgOncol⁩ ⁦@FlavioRochaMD⁩ ⁦@shimulshah73⁩ ⁦@DavendraSohal⁩ 👇🏼👇🏼👇🏼 Treatm…

Agree! @OHSUsurgery @OHSUKnight

Immunotherapy for HCC. The future is now. ⁦@AnnSurgOncol⁩ ⁦@FlavioRochaMD⁩ ⁦@shimulshah73⁩ ⁦@DavendraSohal⁩ 👇🏼👇🏼👇🏼 Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor https://t.co/cKB…

RT @TischCancer: Dr. Thomas Marron @IcahnMountSinai is co-author on this paper.

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 22 additional X posts.